SeLux Diagnostics

OverviewSuggest Edit

SeLux Diagnostics develops universal synthetic amplifier technology equipment for antibiotic susceptibility testing and diagnostics. The Company's Next Generation Phenotyping (NGP) system provides virtually instantaneous AST results, fast-tracking targeted patient therapies so patients can receive the treatments they need. The platform is driven by SeLux’s proprietary assay, which differentiates antibiotic-induced bacterial growth modes with a surface-binding fluorescent amplifier.
TypePrivate
Founded2014
HQCharlestown, US
Websiteseluxdx.com
Employee Ratings4.6

Latest Updates

Employees (est.) (Feb 2020)39(+9%)

Key People/Management at SeLux Diagnostics

Steve Lufkin

Steve Lufkin

CEO
Eric Stern

Eric Stern

CTO & Co-Founder
Aleksandar Vacic

Aleksandar Vacic

President & Co-Founder
Benjamin Spears

Benjamin Spears

Lead Scientist
Nathan Purmort

Nathan Purmort

Principal Engineer
Felicia Giok

Felicia Giok

Scientist
Show more

SeLux Diagnostics Office Locations

SeLux Diagnostics has an office in Charlestown
Charlestown, US (HQ)
56 Roland St #206
Show all (1)

SeLux Diagnostics Financials and Metrics

Summary Metrics

Founding Date

2014

SeLux Diagnostics total Funding

$48.5 m

SeLux Diagnostics latest funding size

$25 m

Time since last funding

a year ago

SeLux Diagnostics investors

SeLux Diagnostics's latest funding round in December 2018 was reported to be $25 m. In total, SeLux Diagnostics has raised $48.5 m
Show all financial metrics

SeLux Diagnostics Online and Social Media Presence

Embed Graph

SeLux Diagnostics News and Updates

Selux Diagnostics Beats Key Contract Milestone, Receives $11.4M in Additional Funding

BOSTON, Oct. 2, 2019 /PRNewswire/ -- Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat superbug infections and combat antibiotic resistance, today announced that it met its first milestone three months ahead of schedule for the milestone-based contract...

Selux Diagnostics Selected to Lead IDWeek 2019 Panel Presentation, Poster Session

BOSTON, Sept. 10, 2019 /PRNewswire/ -- Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat superbug infections and combat antibiotic resistance, today announced its selection to present a poster and participate in a panel discussion at IDWeek 2019 – the...

Selux Diagnostics Announces Selection of Three Abstracts for Poster Sessions at ASM Microbe 2019 Conference

BOSTON, June 10, 2019 /PRNewswire/ -- Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat multidrug resistant organism infections and combat antibiotic resistance, today announced the selection of three Selux-crafted abstracts for poster sessions at the...

SeLux Diagnostics Frequently Asked Questions

  • When was SeLux Diagnostics founded?

    SeLux Diagnostics was founded in 2014.

  • Who are SeLux Diagnostics key executives?

    SeLux Diagnostics's key executives are Steve Lufkin, Eric Stern and Aleksandar Vacic.

  • How many employees does SeLux Diagnostics have?

    SeLux Diagnostics has 39 employees.

  • Who are SeLux Diagnostics competitors?

    Competitors of SeLux Diagnostics include CellAegis Devices, Neurophet and E25Bio.

  • Where is SeLux Diagnostics headquarters?

    SeLux Diagnostics headquarters is located at 56 Roland St #206, Charlestown.

  • Where are SeLux Diagnostics offices?

    SeLux Diagnostics has an office in Charlestown.

  • How many offices does SeLux Diagnostics have?

    SeLux Diagnostics has 1 office.